drugset / Trial / NCT05468489
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Timeline
- Start
- 2022-11-18
- Primary completion
- 2026-02-28
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Serplulimab | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Etoposide | Small molecule | — | — |